Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pulmonary Resection for Metastatic Gastric Cancer

Published byMelissa Quinn Modified over 6 years ago

Similar presentations

Presentation on theme: "Pulmonary Resection for Metastatic Gastric Cancer"— Presentation transcript:

1 Pulmonary Resection for Metastatic Gastric Cancer
Clinton D. Kemp, MD, Mio Kitano, MD, Sid Kerkar, MD, R. Taylor Ripley, MD, Jens U. Marquardt, MD, David S. Schrump, MD, Itzhak Avital, MD  Journal of Thoracic Oncology  Volume 5, Issue 11, Pages (November 2010) DOI: /JTO.0b013e3181ed3514 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, Disease-free survival after gastrectomy. B, Overall survival after gastrectomy. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ed3514) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Disease-free survival after pulmonary metastasectomy. B, Overall survival after pulmonary metastasectomy. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ed3514) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Pulmonary Resection for Metastatic Gastric Cancer"

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma  Rebecca P. Petersen, MD, MSc, Steven.

Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma  Rebecca P. Petersen, MD, MSc, Steven.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 

Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
Jacob A. Klapper, MD, Jeremy L. Davis, MD, R

Jacob A. Klapper, MD, Jeremy L. Davis, MD, R
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Similar presentations

Ads by Google